Skip to main content
Top
Published in: Heart and Vessels 12/2020

01-12-2020 | Transcatheter Aortic Valve Implantation | Original Article

Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis

Authors: Michal Droppa, Tanja K. Rudolph, Jan Baan, Niels-Erik Nielsen, Helmut Baumgartner, Jeroen Vendrik, Maren Froehlich, Oliver Borst, Jochen Wöhrle, Meinrad Gawaz, Paul Potratz, Luis P. Hack, Victor Mauri, Jacek Baranowski, Peter Bramlage, Jana Kurucova, Martin Thoenes, Wolfgang Rottbauer, Tobias Geisler

Published in: Heart and Vessels | Issue 12/2020

Login to get access

Abstract

Permanent pacemaker implantation (PPI) is a widely recognized complication associated with TAVI (incidence up to 20%). Smaller registries have identified several variables associated with PPI. The objective was to validate patient- and transcatheter aortic valve implantation (TAVI)-related procedural variables associated with PPI. We performed a retrospective analysis of patients from six European centers undergoing TAVI with the Edwards SAPIEN 3 prosthesis. Baseline variables and pre-procedural ECG characteristics and CT-scans were taken into account. Data for 1745 patients were collected; 191 (10.9%) required PPI after TAVI. The baseline variables pulmonary hypertension (OR 1.64; 95% CI 1.01–2.59), QRS duration > 117 ms (OR 2.58; 95% CI 1.73–3.84), right bundle branch block (RBBB; OR 5.14; 95% CI 3.39–7.72), left anterior hemi block (OR 1.92; 95% CI 1.19–3.02) and first-degree atrioventricular block (AVB, OR 1.63; 95%CI 1.05–2.46) were significantly associated with PPI. RBBB (OR 8.11; 95% CI 3.19–21.86) and first-degree AVB (OR 2.39; 95% CI 1.18–4.66) remained significantly associated in a multivariate analysis. Procedure-related variables included access site (TF; OR 1.97; 95% CI 1.07–4.05), implanted valve size (29 mm; OR 1.88; 95% CI 1.35–2.59), mean TAVI valve implantation depth below the annulus > 30% (OR 3.75; 95% CI 2.01–6.98). Patients receiving PPI had longer ICU stays and later discharges. Acute kidney injury stage 2/3 was more common in patients with PPI until discharge (15.2 vs. 3.1%; p = 0.007), but was not statistically significant thereafter. Further differences in outcomes at 30 days did not reach significance. The data will aid pre- and post-procedural patient management and prevent adverse long-term outcomes.
Clinical Trial: NCT03497611.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fujita B, Kutting M, Seiffert M, Scholtz S, Egron S, Prashovikj E, Borgermann J, Schafer T, Scholtz W, Preuss R, Gummert J, Steinseifer U, Ensminger SM (2016) Calcium distribution patterns of the aortic valve as a risk factor for the need of permanent pacemaker implantation after transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging 17:1385–1393CrossRef Fujita B, Kutting M, Seiffert M, Scholtz S, Egron S, Prashovikj E, Borgermann J, Schafer T, Scholtz W, Preuss R, Gummert J, Steinseifer U, Ensminger SM (2016) Calcium distribution patterns of the aortic valve as a risk factor for the need of permanent pacemaker implantation after transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging 17:1385–1393CrossRef
2.
go back to reference Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, Mangat G, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Friedman J, Berman D, Makkar RR, Jilaihawi H (2017) A highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging 10:1139–1147CrossRef Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, Mangat G, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Friedman J, Berman D, Makkar RR, Jilaihawi H (2017) A highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging 10:1139–1147CrossRef
3.
go back to reference Tarantini G, Mojoli M, Purita P, Napodano M, D'Onofrio A, Frigo A, Covolo E, Facchin M, Isabella G, Gerosa G, Iliceto S (2015) Unravelling the (arte)fact of increased pacemaker rate with the Edwards SAPIEN 3 valve. EuroIntervention 11:343–350CrossRef Tarantini G, Mojoli M, Purita P, Napodano M, D'Onofrio A, Frigo A, Covolo E, Facchin M, Isabella G, Gerosa G, Iliceto S (2015) Unravelling the (arte)fact of increased pacemaker rate with the Edwards SAPIEN 3 valve. EuroIntervention 11:343–350CrossRef
4.
go back to reference Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, Rosenkranz S, Eghbalzadeh K, Friedrichs K, Wahlers T, Baldus S, Madershahian N, Rudolph TK (2016) Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv 9:2200–2209CrossRef Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, Rosenkranz S, Eghbalzadeh K, Friedrichs K, Wahlers T, Baldus S, Madershahian N, Rudolph TK (2016) Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv 9:2200–2209CrossRef
5.
go back to reference De Torres-Alba F, Kaleschke G, Diller GP, Vormbrock J, Orwat S, Radke R, Reinke F, Fischer D, Reinecke H, Baumgartner H (2016) Changes in the pacemaker rate after transition from edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height. JACC Cardiovasc Interv 9:805–813CrossRef De Torres-Alba F, Kaleschke G, Diller GP, Vormbrock J, Orwat S, Radke R, Reinke F, Fischer D, Reinecke H, Baumgartner H (2016) Changes in the pacemaker rate after transition from edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height. JACC Cardiovasc Interv 9:805–813CrossRef
6.
go back to reference Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM, Kastrati A, Schunkert H, Hengstenberg C (2016) Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 9:244–254CrossRef Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM, Kastrati A, Schunkert H, Hengstenberg C (2016) Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 9:244–254CrossRef
7.
go back to reference Gonska B, Seeger J, Kessler M, von Keil A, Rottbauer W, Wohrle J (2017) Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. Clin Res Cardiol 106:590–597CrossRef Gonska B, Seeger J, Kessler M, von Keil A, Rottbauer W, Wohrle J (2017) Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. Clin Res Cardiol 106:590–597CrossRef
8.
go back to reference Delgado V, Ng AC, Schuijf JD, van der Kley F, Shanks M, Tops LF, van de Veire NR, de Roos A, Kroft LJ, Schalij MJ, Bax JJ (2011) Automated assessment of the aortic root dimensions with multidetector row computed tomography. Ann Thorac Surg 91:716–723CrossRef Delgado V, Ng AC, Schuijf JD, van der Kley F, Shanks M, Tops LF, van de Veire NR, de Roos A, Kroft LJ, Schalij MJ, Bax JJ (2011) Automated assessment of the aortic root dimensions with multidetector row computed tomography. Ann Thorac Surg 91:716–723CrossRef
9.
go back to reference Seiffert M, Fujita B, Avanesov M, Lunau C, Schon G, Conradi L, Prashovikj E, Scholtz S, Borgermann J, Scholtz W, Schafer U, Lund G, Ensminger S, Treede H (2016) Device landing zone calcification and its impact on residual regurgitation after transcatheter aortic valve implantation with different devices. Eur Heart J Cardiovasc Imaging 17:576–584CrossRef Seiffert M, Fujita B, Avanesov M, Lunau C, Schon G, Conradi L, Prashovikj E, Scholtz S, Borgermann J, Scholtz W, Schafer U, Lund G, Ensminger S, Treede H (2016) Device landing zone calcification and its impact on residual regurgitation after transcatheter aortic valve implantation with different devices. Eur Heart J Cardiovasc Imaging 17:576–584CrossRef
10.
go back to reference Glodny B, Helmel B, Trieb T, Schenk C, Taferner B, Unterholzner V, Strasak A, Petersen J (2009) A method for calcium quantification by means of CT coronary angiography using 64-multidetector CT: very high correlation with Agatston and volume scores. Eur Radiol 19:1661–1668CrossRef Glodny B, Helmel B, Trieb T, Schenk C, Taferner B, Unterholzner V, Strasak A, Petersen J (2009) A method for calcium quantification by means of CT coronary angiography using 64-multidetector CT: very high correlation with Agatston and volume scores. Eur Radiol 19:1661–1668CrossRef
11.
go back to reference Kogan A, Sternik L, Beinart R, Shalabi A, Glikson M, Spiegelstein D, Levin S, Raanani E (2015) Permanent pacemaker insertion following isolated aortic valve replacement before and after the introduction of TAVI. Pacing Clin Electrophysiol 38:424–430CrossRef Kogan A, Sternik L, Beinart R, Shalabi A, Glikson M, Spiegelstein D, Levin S, Raanani E (2015) Permanent pacemaker insertion following isolated aortic valve replacement before and after the introduction of TAVI. Pacing Clin Electrophysiol 38:424–430CrossRef
12.
go back to reference van Rosendael PJ, Delgado V, Bax JJ (2018) Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J 39:2003–2013CrossRef van Rosendael PJ, Delgado V, Bax JJ (2018) Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J 39:2003–2013CrossRef
13.
go back to reference Husser O, Pellegrini C, Kim WK, Holzamer A, Pilgrim T, Toggweiler S, Schafer U, Blumenstein J, Deuschl F, Rheude T, Joner M, Hilker M, Hengstenberg C, Mollmann H (2019) Transcatheter valve SELECTion in patients with right bundle branch block and impact on pacemaker implantations. JACC Cardiovasc Interv 12:1781–1793CrossRef Husser O, Pellegrini C, Kim WK, Holzamer A, Pilgrim T, Toggweiler S, Schafer U, Blumenstein J, Deuschl F, Rheude T, Joner M, Hilker M, Hengstenberg C, Mollmann H (2019) Transcatheter valve SELECTion in patients with right bundle branch block and impact on pacemaker implantations. JACC Cardiovasc Interv 12:1781–1793CrossRef
14.
go back to reference Kaneko H, Hoelschermann F, Seifert M, Tambor G, Okamoto M, Moeller V, Neuss M, Butter C (2019) Predictors of permanent pacemaker implantation after transcatheter aortic valve implantation for aortic stenosis using Medtronic new generation self-expanding CoreValve Evolut R. Heart Vessels 34:360–367CrossRef Kaneko H, Hoelschermann F, Seifert M, Tambor G, Okamoto M, Moeller V, Neuss M, Butter C (2019) Predictors of permanent pacemaker implantation after transcatheter aortic valve implantation for aortic stenosis using Medtronic new generation self-expanding CoreValve Evolut R. Heart Vessels 34:360–367CrossRef
15.
go back to reference Mauri V, Deuschl F, Frohn T, Schofer N, Linder M, Kuhn E, Schaefer A, Rudolph V, Madershahian N, Conradi L, Rudolph TK, Schafer U (2018) Predictors of paravalvular regurgitation and permanent pacemaker implantation after TAVR with a next-generation self-expanding device. Clin Res Cardiol 107:688–697CrossRef Mauri V, Deuschl F, Frohn T, Schofer N, Linder M, Kuhn E, Schaefer A, Rudolph V, Madershahian N, Conradi L, Rudolph TK, Schafer U (2018) Predictors of paravalvular regurgitation and permanent pacemaker implantation after TAVR with a next-generation self-expanding device. Clin Res Cardiol 107:688–697CrossRef
16.
go back to reference Bacik P, Poliacikova P, Kaliska G (2018) Who needs a permanent pacemaker after transcatheter aortic valve implantation? Bratisl Lek Listy 119:560–565 Bacik P, Poliacikova P, Kaliska G (2018) Who needs a permanent pacemaker after transcatheter aortic valve implantation? Bratisl Lek Listy 119:560–565
17.
go back to reference Tichelbacker T, Bergau L, Puls M, Friede T, Mutze T, Maier LS, Frey N, Hasenfuss G, Zabel M, Jacobshagen C, Sossalla S (2018) Insights into permanent pacemaker implantation following TAVR in a real-world cohort. PLoS ONE 13:e0204503CrossRef Tichelbacker T, Bergau L, Puls M, Friede T, Mutze T, Maier LS, Frey N, Hasenfuss G, Zabel M, Jacobshagen C, Sossalla S (2018) Insights into permanent pacemaker implantation following TAVR in a real-world cohort. PLoS ONE 13:e0204503CrossRef
18.
go back to reference Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, Wenaweser P, Windecker S (2014) Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol 64:129–140CrossRef Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, Wenaweser P, Windecker S (2014) Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol 64:129–140CrossRef
19.
go back to reference Steinberg BA, Harrison JK, Frazier-Mills C, Hughes GC, Piccini JP (2012) Cardiac conduction system disease after transcatheter aortic valve replacement. Am Heart J 164:664–671CrossRef Steinberg BA, Harrison JK, Frazier-Mills C, Hughes GC, Piccini JP (2012) Cardiac conduction system disease after transcatheter aortic valve replacement. Am Heart J 164:664–671CrossRef
20.
go back to reference Toggweiler S, Kobza R (2018) Pacemaker implantation after transcatheter aortic valve: why is this still happening? J Thorac Dis 10:S3614–S3619CrossRef Toggweiler S, Kobza R (2018) Pacemaker implantation after transcatheter aortic valve: why is this still happening? J Thorac Dis 10:S3614–S3619CrossRef
21.
go back to reference Munoz-Garcia AJ, Hernandez-Garcia JM, Jimenez-Navarro MF, Alonso-Briales JH, Dominguez-Franco AJ, Fernandez-Pastor J, Pena Hernandez J, Barrera Cordero A, Alzueta Rodriguez J, de Teresa-Galvan E (2012) Factors predicting and having an impact on the need for a permanent pacemaker after CoreValve prosthesis implantation using the new Accutrak delivery catheter system. JACC Cardiovasc Interv 5:533–539CrossRef Munoz-Garcia AJ, Hernandez-Garcia JM, Jimenez-Navarro MF, Alonso-Briales JH, Dominguez-Franco AJ, Fernandez-Pastor J, Pena Hernandez J, Barrera Cordero A, Alzueta Rodriguez J, de Teresa-Galvan E (2012) Factors predicting and having an impact on the need for a permanent pacemaker after CoreValve prosthesis implantation using the new Accutrak delivery catheter system. JACC Cardiovasc Interv 5:533–539CrossRef
22.
go back to reference Jilaihawi H, Zhao Z, Du R, Staniloae C, Saric M, Neuburger PJ, Querijero M, Vainrib A, Hisamoto K, Ibrahim H, Collins T, Clark E, Pushkar I, Bamira D, Benenstein R, Tariq A, Williams M (2019) Minimizing permanent pacemaker following repositionable self-expanding transcatheter aortic valve replacement. JACC Cardiovasc Interv 12:1796–1807CrossRef Jilaihawi H, Zhao Z, Du R, Staniloae C, Saric M, Neuburger PJ, Querijero M, Vainrib A, Hisamoto K, Ibrahim H, Collins T, Clark E, Pushkar I, Bamira D, Benenstein R, Tariq A, Williams M (2019) Minimizing permanent pacemaker following repositionable self-expanding transcatheter aortic valve replacement. JACC Cardiovasc Interv 12:1796–1807CrossRef
23.
go back to reference Stathogiannis K, Toutouzas K, Drakopoulou M, Latsios G, Synetos A, Michelongona A, Kaitozis O, Trantalis G, Penesopoulou V, Tsiamis E, Tousoulis D (2017) Abstract 21266: valve oversizing in transcatheter aortic valve replacement: impact on outcome. Circulation 136:A21266–A21266 Stathogiannis K, Toutouzas K, Drakopoulou M, Latsios G, Synetos A, Michelongona A, Kaitozis O, Trantalis G, Penesopoulou V, Tsiamis E, Tousoulis D (2017) Abstract 21266: valve oversizing in transcatheter aortic valve replacement: impact on outcome. Circulation 136:A21266–A21266
24.
go back to reference Vahanian A, Himbert D (2011) Transcatheter aortic valve implantation: could it be done without prior balloon valvuloplasty? JACC Cardiovasc Interv 4:758–759CrossRef Vahanian A, Himbert D (2011) Transcatheter aortic valve implantation: could it be done without prior balloon valvuloplasty? JACC Cardiovasc Interv 4:758–759CrossRef
25.
go back to reference Toutouzas K, Benetos G, Voudris V, Drakopoulou M, Stathogiannis K, Latsios G, Synetos A, Antonopoulos A, Kosmas E, Iakovou I, Katsimagklis G, Mastrokostopoulos A, Moraitis S, Zeniou V, Danenberg H, Vavuranakis M, Tousoulis D (2019) Pre-dilatation versus no pre-dilatation for implantation of a self-expanding valve in all comers undergoing TAVR: the DIRECT Trial. JACC Cardiovasc Interv 12:767–777CrossRef Toutouzas K, Benetos G, Voudris V, Drakopoulou M, Stathogiannis K, Latsios G, Synetos A, Antonopoulos A, Kosmas E, Iakovou I, Katsimagklis G, Mastrokostopoulos A, Moraitis S, Zeniou V, Danenberg H, Vavuranakis M, Tousoulis D (2019) Pre-dilatation versus no pre-dilatation for implantation of a self-expanding valve in all comers undergoing TAVR: the DIRECT Trial. JACC Cardiovasc Interv 12:767–777CrossRef
26.
go back to reference Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA 3rd, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD, American College of Cardiology F, American Heart Association Task Force on Practice G, Heart Rhythm S (2013) 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 61:e6–75CrossRef Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA 3rd, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD, American College of Cardiology F, American Heart Association Task Force on Practice G, Heart Rhythm S (2013) 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 61:e6–75CrossRef
27.
go back to reference Shaw DB, Kekwick CA, Veale D, Gowers J, Whistance T (1985) Survival in second degree atrioventricular block. Br Heart J 53:587–593CrossRef Shaw DB, Kekwick CA, Veale D, Gowers J, Whistance T (1985) Survival in second degree atrioventricular block. Br Heart J 53:587–593CrossRef
28.
go back to reference Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SK, Marinchak RA, Estes NA 3rd, Mitchell GF, Lieberman EH, Mangione CM, Goldman L (1998) Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med 338:1097–1104CrossRef Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB, Huang SK, Marinchak RA, Estes NA 3rd, Mitchell GF, Lieberman EH, Mangione CM, Goldman L (1998) Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med 338:1097–1104CrossRef
29.
go back to reference Paton MF, Gierula J, Jamil HA, Lowry JE, Byrom R, Gillott RG, Chumun H, Cubbon RM, Cairns DA, Stocken DD, Kearney MT, Witte KK (2019) Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ Open 9:e028613CrossRef Paton MF, Gierula J, Jamil HA, Lowry JE, Byrom R, Gillott RG, Chumun H, Cubbon RM, Cairns DA, Stocken DD, Kearney MT, Witte KK (2019) Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ Open 9:e028613CrossRef
30.
go back to reference Thackray S, Witte KA, Nikitin NP, Clark AL, Kaye GC, Cleland JGF (2003) The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 24:1143–1152CrossRef Thackray S, Witte KA, Nikitin NP, Clark AL, Kaye GC, Cleland JGF (2003) The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 24:1143–1152CrossRef
31.
go back to reference Gierula J, Jamil HA, Byrom R, Joy ER, Cubbon RM, Kearney MT, Witte KK (2014) Pacing-associated left ventricular dysfunction? Think reprogramming first! Heart 100:765–769CrossRef Gierula J, Jamil HA, Byrom R, Joy ER, Cubbon RM, Kearney MT, Witte KK (2014) Pacing-associated left ventricular dysfunction? Think reprogramming first! Heart 100:765–769CrossRef
32.
go back to reference Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L, EuroHeart Survey I, Heart Failure Association ESoC (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725–2736CrossRef Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L, EuroHeart Survey I, Heart Failure Association ESoC (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725–2736CrossRef
33.
go back to reference Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, Investigators P (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695–1705CrossRef Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, Investigators P (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695–1705CrossRef
34.
go back to reference Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial I (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706–1715CrossRef Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ, Evolut Low Risk Trial I (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706–1715CrossRef
35.
go back to reference Ielasi A, Latib A, Tespili M, Donatelli F (2019) Current results and remaining challenges of trans-catheter aortic valve replacement expansion in intermediate and low risk patients. Int J Cardiol Heart Vasc 23:100375 Ielasi A, Latib A, Tespili M, Donatelli F (2019) Current results and remaining challenges of trans-catheter aortic valve replacement expansion in intermediate and low risk patients. Int J Cardiol Heart Vasc 23:100375
36.
go back to reference Mangieri A, Montalto C, Pagnesi M, Lanzillo G, Demir O, Testa L, Colombo A, Latib A (2018) TAVI and post procedural cardiac conduction abnormalities. Front Cardiovasc Med 5:85CrossRef Mangieri A, Montalto C, Pagnesi M, Lanzillo G, Demir O, Testa L, Colombo A, Latib A (2018) TAVI and post procedural cardiac conduction abnormalities. Front Cardiovasc Med 5:85CrossRef
37.
go back to reference Weber M, Sinning JM, Hammerstingl C, Werner N, Grube E, Nickenig G (2015) Permanent pacemaker implantation after TAVR—predictors and impact on outcomes. Interv Cardiol 10:98–102CrossRef Weber M, Sinning JM, Hammerstingl C, Werner N, Grube E, Nickenig G (2015) Permanent pacemaker implantation after TAVR—predictors and impact on outcomes. Interv Cardiol 10:98–102CrossRef
38.
go back to reference Schwerg M, Fulde F, Dreger H, Poller WC, Stangl K, Laule M (2016) Optimized implantation height of the Edwards SAPIEN 3 valve to minimize pacemaker implantation after TAVI. J Interv Cardiol 29:370–374CrossRef Schwerg M, Fulde F, Dreger H, Poller WC, Stangl K, Laule M (2016) Optimized implantation height of the Edwards SAPIEN 3 valve to minimize pacemaker implantation after TAVI. J Interv Cardiol 29:370–374CrossRef
Metadata
Title
Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis
Authors
Michal Droppa
Tanja K. Rudolph
Jan Baan
Niels-Erik Nielsen
Helmut Baumgartner
Jeroen Vendrik
Maren Froehlich
Oliver Borst
Jochen Wöhrle
Meinrad Gawaz
Paul Potratz
Luis P. Hack
Victor Mauri
Jacek Baranowski
Peter Bramlage
Jana Kurucova
Martin Thoenes
Wolfgang Rottbauer
Tobias Geisler
Publication date
01-12-2020
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 12/2020
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-020-01653-6

Other articles of this Issue 12/2020

Heart and Vessels 12/2020 Go to the issue